ALLO

Allogene Therapeutics, Inc. NASDAQ

Healthcare ·Biotechnology ·US · allogene.com

$2.26

Pre-mkt $2.28 +0.88%

Mkt Cap $551.1M

52w Low $0.86 38.9% of range 52w High $4.46

50d MA $2.41 200d MA $1.62

P/E (TTM) -2.5x

EV/EBITDA -1.7x

P/B 1.6x

Debt/Equity 0.3x

ROE -65.2%

P/FCF -2.0x

RSI (14) —

ATR (14) —

Beta 0.54

50d MA $2.41

200d MA $1.62

Avg Volume 9.6M

About

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The compan…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Mar 12, 2026	AMC	-0.25	-0.17	+32.0%	2.47	+3.6%	-2.8%	-1.2%	-8.1%	-13.0%	-10.1%	+23.9%	—
Nov 6, 2025	AMC	-0.23	-0.19	+17.4%	1.05	+0.0%	+12.4%	+12.4%	+18.1%	+17.1%	+14.3%	+38.1%	—
Aug 13, 2025	AMC	-0.28	-0.23	+17.9%	1.04	+1.0%	+2.9%	+5.8%	+4.8%	+1.0%	+1.9%	+8.7%	—
May 13, 2025	AMC	-0.28	-0.28	+0.0%	1.13	-2.7%	-15.7%	-3.5%	-1.8%	-3.5%	+2.7%	+23.9%	—
Mar 13, 2025	AMC	-0.34	-0.28	+17.6%	1.89	+7.4%	+2.6%	-2.1%	-10.6%	-10.6%	-13.8%	-24.3%	—
Nov 7, 2024	AMC	-0.34	-0.27	+20.6%	3.19	+1.6%	-3.4%	-3.1%	-11.0%	-14.7%	-22.9%	-28.8%	—
Aug 7, 2024	AMC	-0.35	-0.32	+8.6%	2.47	+5.3%	-4.5%	-6.1%	-4.5%	-4.9%	-8.9%	-2.4%	—
May 13, 2024	AMC	-0.38	-0.38	+0.0%	2.90	+12.1%	+2.1%	+2.8%	+3.8%	-4.5%	-10.7%	-11.4%	—
Mar 14, 2024	AMC	-0.47	-0.43	+8.5%	4.50	-1.1%	+3.6%	-6.7%	-2.4%	-1.6%	-2.7%	-21.1%	—
Nov 2, 2023	AMC	-0.53	-0.37	+30.2%	2.97	+5.4%	+17.8%	+6.4%	+10.4%	-3.7%	-15.3%	-13.8%	—
Aug 2, 2023	AMC	-0.59	-0.53	+10.2%	4.69	+3.0%	+9.6%	-2.1%	-9.4%	-4.9%	-7.5%	-13.6%	—
May 3, 2023	AMC	-0.63	-0.68	-7.9%	5.72	-0.3%	+12.8%	+15.4%	+10.5%	+8.9%	+11.2%	-1.9%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.17	$2.23	+2.8%	+9.2%	+10.1%	+11.5%	+6.9%	+10.1%
Apr 16	JP Morgan	Upgrade	Underweight → Neutral	—	$2.17	$2.23	+2.8%	+9.2%	+10.1%	+11.5%	+6.9%	+10.1%
Apr 15	Jefferies	Maintains	Buy → Buy	—	$2.28	$1.90	-16.7%	-4.8%	+3.9%	+4.8%	+6.1%	+1.8%
Apr 14	Argus	Maintains	Market Perform → Market Perform	—	$3.06	$3.03	-1.0%	-25.5%	-29.1%	-22.5%	-21.9%	-20.9%
Apr 14	Baird	Maintains	Outperform → Outperform	—	$3.06	$3.03	-1.0%	-25.5%	-29.1%	-22.5%	-21.9%	-20.9%
Apr 14	Bernstein	Maintains	Market Perform → Market Perform	—	$3.06	$3.03	-1.0%	-25.5%	-29.1%	-22.5%	-21.9%	-20.9%
Apr 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.06	$3.03	-1.0%	-25.5%	-29.1%	-22.5%	-21.9%	-20.9%
Apr 14	Citizens	Maintains	Market Outperform → Market Outperform	—	$3.06	$3.03	-1.0%	-25.5%	-29.1%	-22.5%	-21.9%	-20.9%
Mar 13	Piper Sandler	Maintains	Overweight → Overweight	—	$2.47	$2.56	+3.6%	-2.8%	-1.2%	-8.1%	-13.0%	-10.1%
Mar 13	Canaccord Genuity	Maintains	Buy → Buy	—	$2.47	$2.56	+3.6%	-2.8%	-1.2%	-8.1%	-13.0%	-10.1%
Jan 9	Citizens	Upgrade	Market Perform → Market Outperform	—	$1.49	$1.66	+11.4%	+14.8%	+12.1%	+10.1%	+14.1%	+8.1%
Oct 10	JP Morgan	Downgrade	Neutral → Underweight	—	$1.51	$1.44	-4.6%	-18.5%	-15.9%	-18.5%	-15.9%	-15.9%
Aug 4	JMP Securities	Maintains	Market Perform → Market Perform	—	$1.08	$1.11	+2.8%	+1.9%	+3.7%	-1.9%	-2.8%	-3.7%
Aug 4	JP Morgan	Downgrade	Overweight → Neutral	—	$1.08	$1.11	+2.8%	+1.9%	+3.7%	-1.9%	-2.8%	-3.7%
Aug 1	Oppenheimer	Maintains	Outperform → Outperform	—	$1.23	$1.23	+0.0%	-12.2%	-10.6%	-8.9%	-13.8%	-14.6%
May 15	Citigroup	Maintains	Buy → Buy	—	$0.95	$0.95	-0.3%	+14.4%	+16.5%	+14.4%	+21.7%	+16.5%
May 14	Piper Sandler	Maintains	Overweight → Overweight	—	$1.13	$1.10	-2.7%	-15.7%	-3.5%	-1.8%	-3.5%	+2.7%
May 14	Baird	Maintains	Outperform → Outperform	—	$1.13	$1.10	-2.7%	-15.7%	-3.5%	-1.8%	-3.5%	+2.7%
May 14	Truist	Maintains	Buy → Buy	—	$1.13	$1.10	-2.7%	-15.7%	-3.5%	-1.8%	-3.5%	+2.7%
May 14	Oppenheimer	Maintains	Outperform → Outperform	—	$1.13	$1.10	-2.7%	-15.7%	-3.5%	-1.8%	-3.5%	+2.7%
May 14	RBC Capital	Maintains	Outperform → Outperform	—	$1.13	$1.10	-2.7%	-15.7%	-3.5%	-1.8%	-3.5%	+2.7%
Mar 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.69	$1.69	+0.0%	+0.0%	-3.6%	-4.1%	-0.6%	-5.3%
Mar 14	RBC Capital	Maintains	Outperform → Outperform	—	$1.89	$2.03	+7.4%	+2.6%	-2.1%	-10.6%	-10.6%	-13.8%
Mar 14	Canaccord Genuity	Maintains	Buy → Buy	—	$1.89	$2.03	+7.4%	+2.6%	-2.1%	-10.6%	-10.6%	-13.8%
Mar 14	Citizens Capital Markets	Upgrade	Market Perform → Market Outperform	—	$1.89	$2.03	+7.4%	+2.6%	-2.1%	-10.6%	-10.6%	-13.8%
Nov 14	Piper Sandler	Maintains	Overweight → Overweight	—	$2.72	$2.72	+0.0%	-9.6%	-16.5%	-21.0%	-22.1%	-24.6%
Nov 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.19	$3.24	+1.6%	-3.4%	-3.1%	-11.0%	-14.7%	-22.9%
Oct 30	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.80	$2.74	-2.1%	-5.7%	-8.6%	-2.9%	+7.1%	+6.8%
Aug 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.25	$2.30	+2.2%	+2.2%	+1.8%	+17.8%	+17.3%	+21.8%
Aug 9	Citigroup	Maintains	Buy → Buy	—	$2.36	$2.40	+1.7%	-1.7%	+0.0%	-0.4%	-4.7%	-2.5%
Aug 9	Truist	Maintains	Buy → Buy	—	$2.36	$2.40	+1.7%	-1.7%	+0.0%	-0.4%	-4.7%	-2.5%
Aug 8	Canaccord Genuity	Maintains	Buy → Buy	—	$2.47	$2.60	+5.3%	-4.5%	-6.1%	-4.5%	-4.9%	-8.9%
May 21	Oppenheimer	Maintains	Outperform → Outperform	—	$2.59	$2.89	+11.6%	+3.9%	+2.7%	-1.9%	-2.7%	-6.2%
May 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.98	$3.00	+0.7%	+1.0%	-7.0%	-13.1%	-9.7%	-10.7%
May 15	Truist	Maintains	Buy → Buy	—	$2.96	$3.00	+1.4%	+0.7%	+1.7%	-6.4%	-12.5%	-9.1%
May 14	Stifel	Maintains	Hold → Hold	—	$2.90	$3.25	+12.1%	+2.1%	+2.8%	+3.8%	-4.5%	-10.7%
Mar 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.20	$4.15	-1.2%	+4.5%	+5.5%	+4.3%	+1.4%	+2.1%
Mar 15	RBC Capital	Maintains	Outperform → Outperform	—	$4.50	$4.45	-1.1%	+3.6%	-6.7%	-2.4%	-1.6%	-2.7%
Feb 27	JP Morgan	Maintains	Overweight → Overweight	—	$4.63	$4.75	+2.6%	+11.0%	+10.6%	+6.0%	+6.7%	+17.9%
Jan 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.20	$3.19	-0.3%	-3.4%	-1.2%	+0.3%	-1.2%	+0.0%
Jan 5	JMP Securities	Downgrade	Market Outperform → Market Perform	—	$3.39	$2.80	-17.4%	-13.9%	-7.7%	-10.0%	-6.5%	-5.3%
Jan 5	Guggenheim	Downgrade	Buy → Neutral	—	$3.39	$2.80	-17.4%	-13.9%	-7.7%	-10.0%	-6.5%	-5.3%
Nov 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.65	$2.64	-0.4%	+2.6%	+6.0%	+11.3%	+12.8%	+6.4%
Sep 25	JP Morgan	Maintains	Overweight → Overweight	—	$3.65	$3.63	-0.5%	-3.8%	-7.9%	-7.1%	-6.6%	-13.2%
Aug 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.59	$4.61	+0.4%	-7.4%	-2.8%	-5.4%	-8.3%	-8.5%
Aug 3	EF Hutton	Maintains	Buy → Buy	—	$4.69	$4.83	+3.0%	+9.6%	-2.1%	-9.4%	-4.9%	-7.5%
Aug 3	Oppenheimer	Maintains	Outperform → Outperform	—	$4.69	$4.83	+3.0%	+9.6%	-2.1%	-9.4%	-4.9%	-7.5%
Jul 12	Truist	Maintains	Buy → Buy	—	$5.79	$5.89	+1.7%	+0.2%	-9.8%	-14.3%	-8.6%	-8.1%
Jun 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.85	$4.79	-1.2%	-0.8%	-2.9%	-3.1%	-2.1%	-2.5%
Jun 16	Canaccord Genuity	Maintains	Buy → Buy	—	$4.97	$4.99	+0.4%	-2.4%	-3.2%	-5.2%	-5.4%	-4.4%

Recent Filings

8-K

Unknown — 8-K Filing

Allogene Therapeutics completed a public offering, so the company raised capital for operations and clinical development, though dilution to existing shareholders occurred.

Apr 15

8-K

Unknown — 8-K Filing

This minimal 8-K disclosure provides no material information, suggesting either a routine administrative filing or potential missing substantive event details that investors need to understand Allogene's actual business developments and financial implications.

Apr 13

8-K

Unknown — 8-K Filing

Allogene's cema-cel shows compelling efficacy with 58.3% MRD negativity versus 16.7% in controls, suggesting strong clinical potential that could support regulatory approval and justify the therapy's commercial value.

Apr 13

8-K

Unknown — 8-K Filing

Allogene's imminent ALPHA3 interim data release could be a major catalyst—positive results would validate its allogeneic CAR-T platform and potentially drive significant stock appreciation for this clinical-stage biotech.

Mar 12

Data updated apr 24, 2026 5:21pm · Source: massive.com